PHARMACEUTICAL INDUSTRY
PARALLEL TRADE / BLISTER PACKING
Kohl lobbies in Brussels
The initiative, founded in July, with offices in Berlin and Brussels, has set itself the aim of promoting cost efficiency and innovation in European healthcare. In more concrete terms and translated into the entrepreneurial interests of the members, this means: affordable patented medicines (parallel imports), biosimilars & generic drugs, ambient assisted living (homecare/industrial blister packing).
Kohl does not keep his intentions secret: In order to position the concerns of the member firms, Costeff is to lobby at the European Commission, the Council of Ministers, the EU Parliament and other policy makers in Brussels and Strasbourg. Costeff’s sphere of action is ambitious and stretches from conducting symposiums to exerting influence on legislation amendments – for example, the introduction of the one-week blister pack.
In Brussels around 80 industry representatives and delegates followed up on the invitation from the union head, Kohl; the initiative was presented for one hour. As guest speaker, the German MEP Jo Leinen (social democrats) praised the initiative; Jerome Bôehm from the European Commission spoke about the challenges of the health system, but regarding Costeff he maintained a low profile.
Costeff advocates free movement of goods, fair competition in the health system and a uniform legal framework of the EU. Cost efficiency should be projected beyond pure economy measures and should promote innovation; ultimately these are two sides of the same coin, claimed Kohl. Parallel traders, manufacturers and logisticians, but also health authorities, and patient, doctor, clinic and pharmacist associations are invited to join Costeff.
Until now the existing members are represented in the union multiple times: directly as a company and via the trade association of parallel traders in Germany – which is in principle identically compiled. Kohl has even brought all of the subsidiaries into the union – 7x4, Assist, Avie, kohlpharma and MTK.
Patrick Hollstein, Mon, November 16, 2009 11:38am CET
News
"Germany is not an attractive location for business"
With half-yearly acquisitions between 1999 and 2008 the Icelandic generic drug manufacturer Actavis advanced to become one of
...more
Dethlefs new general manager at Ratiopharm/Teva
Dr. Sven Dethlefs, previously CEO at Teva Germany, is to become general manager at Ratiopharm. Dethlefs will be responsible
...more
Sanofi storms generic drug market
French pharmaceutical company Sanofi-Aventis gradually gains importance in German generics market, putting current market
...more
Teva acquires Ratiopharm
The Israeli generic drug company Teva acquires German manufacturer Ratiopharm. The purchase price for Germany's second
...more




News Alert
RSS
Mobile
Home
Dossier
EU Special
Phoenix Special
